Our drug-target discovery investigations of PANK proteins also relies on the essentiality of PANK proteins for CoA biosynthesis and aims to exploit the redundancies in the PANK proteins to specifically target PANK1-deleted cancers, which can be co-deleted as part of the PTEN tumor suppressor locus, whose homozygous deletion is associated with poor prognosis, high malignancy, and resistance to both conventional chemotherapy and precision oncology drugs [22,23,24,25,26]. This evidence concerns the gene PANK1 and neoplasm.